Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Hemophagocytic syndrome secondary to SARS-Cov-2 infection: a case report.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : BioMed Central, [2001-
    • الموضوع:
      COVID-19/*complications ; Cytokine Release Syndrome/*diagnosis ; Lymphohistiocytosis, Hemophagocytic/*diagnosis; COVID-19/diagnosis ; Cytokine Release Syndrome/etiology ; Female ; Humans ; Lymphohistiocytosis, Hemophagocytic/complications ; Lymphohistiocytosis, Hemophagocytic/drug therapy ; Lymphohistiocytosis, Hemophagocytic/etiology ; Middle Aged ; Pandemics ; SARS-CoV-2
    • نبذة مختصرة :
      Background: Hemophagocytic syndrome (HPS) is a severe hyperinflammatory disease, whose diagnosis is based on the HLH-2004 criteria. In secondary forms of HLH (sHLH), the primary goal is treating the triggering factors such as COVID-19 (Coronavirus disease 2019). The link between the cytokine storm related to COVID-19 and development of sHLH has already been reported since the onset of pandemic, but little is known about clinical manifestations of HLH which develop after the patient's recovery from mild symptomatic or asymptomatic Sars-CoV-2 infection.
      Case Presentation: We describe the case of a woman diagnosed with sHLH related to previous Sars-CoV-2 infection and successfully treated with steroids, colchicine, etoposide and ruxolitinib.
      Conclusions: Our report suggests that HLH-like syndrome might be secondary to Sars-CoV-2 infection, even if the patient utterly recovered from the mildly symptomatic viral infection. In addition, we underline the treatment with low dose ruxolitinib plus etoposide as a potential choice for Sars-CoV-2 infection related HLH.
      (© 2021. The Author(s).)
    • References:
      Front Immunol. 2020 May 28;11:1130. (PMID: 32574264)
      Trends Cardiovasc Med. 2015 Feb;25(2):129-36. (PMID: 25454379)
      Cancer. 2017 Sep 1;123(17):3229-3240. (PMID: 28621800)
      Lancet Infect Dis. 2007 Dec;7(12):814-22. (PMID: 18045564)
      Lancet. 2014 Apr 26;383(9927):1503-1516. (PMID: 24290661)
      J Immunother Cancer. 2018 Jun 5;6(1):49. (PMID: 29871698)
      Blood Rev. 2021 Jan;45:100707. (PMID: 32425294)
      Rheumatol Int. 2021 Jan;41(1):7-18. (PMID: 32588191)
      Curr Opin Immunol. 2017 Dec;49:20-26. (PMID: 28866302)
      Arthritis Rheumatol. 2014 Sep;66(9):2613-20. (PMID: 24782338)
      Blood. 2016 Jun 2;127(22):2672-81. (PMID: 26966089)
      Pediatr Blood Cancer. 2007 Feb;48(2):124-31. (PMID: 16937360)
      Semin Hematol. 2020 Jan;57(1):26-30. (PMID: 32690141)
      Blood. 2019 Jun 6;133(23):2465-2477. (PMID: 30992265)
      Crit Care. 2020 Jun 18;24(1):360. (PMID: 32552865)
    • Contributed Indexing:
      Keywords: COVID-19; Case report; Hemophagocytic syndrome; Polyserositis
    • الموضوع:
      Date Created: 20210814 Date Completed: 20210831 Latest Revision: 20210831
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC8361241
    • الرقم المعرف:
      10.1186/s12879-021-06532-7
    • الرقم المعرف:
      34388982